• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SiNtx Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    2/18/26 8:35:38 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care
    Get the next $SINT alert in real time by email
    false 0001269026 0001269026 2026-02-18 2026-02-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): February 18, 2026

     

    SINTX Technologies, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-33624   84-1375299

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    1885 West 2100 South

    Salt Lake City, UT 84119

    (Address of principal executive offices, including Zip Code)

     

    Registrant’s telephone number, including area code: (801) 839-3500

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class:   Trading Symbol(s):   Name of each exchange on which registered:
    Common Stock, par value $0.01 per share   SINT   The NASDAQ Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    (b) Change in Officer Position

     

    Effective March 16, 2026, Eric Olson will cease serving as President of SINTX Technologies, Inc. (the “Company”) and will continue to serve as Chairman of the Board and Chief Executive Officer of the Company.

     

    (c) Appointment of President

     

    On February 17, 2026, the Company announced the appointment of Ryan Elmore as President of the Company, effective March 16, 2026. Mr. Elmore will report to the Company’s Chief Executive Officer.

     

    Mr. Elmore has over 20 years of leadership experience in the medical device and life sciences industries, including senior executive roles with responsibility for research and development, commercial operations, and international business expansion. Prior to joining the Company, Mr. Elmore served in various leadership positions at Invibio, a division of Victrex plc. He most recently served as Core Business Director since September 2021, where he was responsible for commercial leadership within advanced biomaterials and medical device markets. From October 2010 to November 2021, he served as Global Head of Sales, with responsibility for global commercial strategy and sales execution.

     

    There are no arrangements or understandings between Mr. Elmore and any other person pursuant to which he was selected as President. There are no family relationships between Mr. Elmore and any director or executive officer of the Company, and there are no related party transactions involving Mr. Elmore that would require disclosure under Item 404(a) of Regulation S-K.

     

    (c)(3) Executive Employment Agreement

     

    In connection with his appointment, the Company entered into an Executive Employment Agreement with Mr. Elmore, effective February 6, 2026, with an employment commencement date of March 16, 2026.

     

    Pursuant to the agreement:

     

    ●Base Salary: $375,000 per year.
    ●Annual Bonus: Eligible for an annual cash bonus with a target opportunity of 35% of base salary. Mr. Elmore’s annual bonus for his first year of employment is guaranteed.
    ●Sign-On Bonus: $100,000 payable upon commencement of employment, subject to repayment if Mr. Elmore voluntarily terminates employment within twelve months of his start date.
    ●Equity Awards: Upon commencement of employment, Mr. Elmore will receive a restricted stock unit award with a grant date value of $300,000, with 20% vesting on the grant date and the remainder vesting in equal installments over the following 24 months, subject to continued employment. He will also be eligible to receive additional equity awards, including awards tied to the achievement of specified international business milestones.
    ●Benefits: Eligible to participate in the Company’s employee benefit plans available to senior executives.

     

     

     

     

    The agreement provides that if Mr. Elmore’s employment is terminated by the Company without cause or by Mr. Elmore for good reason, he will be entitled to receive accrued compensation and severance benefits, including a cash payment equal to two times the sum of his base salary and target bonus and continued health benefit coverage (or cash payments in lieu thereof) for up to 24 months, subject to execution of a release of claims. The agreement provides for enhanced severance protections in connection with certain change in control events.

     

    Mr. Elmore’s employment is subject to customary pre-employment conditions, including successful completion of background and drug screening.

     

    The foregoing description of the Executive Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the agreement, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    10.1*   Executive Employment Agreement, dated February 6, 2026, by and between SINTX Technologies, Inc. and Ryan Elmore
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    *Certain immaterial provisions of the Executive Employment Agreement have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because the omitted information is not material and would likely cause competitive harm to the Company if publicly disclosed.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

          SINTX Technologies, Inc.
             
    Date: February 18, 2026   By: /s/ Eric K. Olson
            Eric K. Olson
            Chief Executive Officer

     

     

     

    Get the next $SINT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SINT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SINT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 4–5

    SALT LAKE CITY, Utah, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon-nitride-based medical technologies, today announced that its management team will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, to be held February 4–5, 2026. The Company's participation comes at an important stage in its evolution, following a period of operational restructuring, enhanced financial discipline, and a renewed strategic focus on its core medical-technology platforms. With a more streamlined cost structure, greater visibility into its balance-sheet, and sev

    1/29/26 9:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies to Participate in Sidoti & Company Investor Conference

    SALT LAKE CITY, Utah, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), today announced that management will be presenting at Sidoti & Company's Year End Virtual Investor Conference, held December 10-11, 2025. Sidoti's Year End Virtual Investor ConferenceDates: December 10-11, 2025Presentation Date and Time: Wednesday, December 10, 2025 at 3:15 P.M. ETWebcast: https://sidoti.zoom.us/webinar/register/WN_O_OnAvXpQki63dk_9JbUYw To schedule a one-on-one meeting with SINTX Technologies' management team, please email KCSA Strategic Communications at [email protected]. To be added to the Sintx Technologies email distribution list, please email Si

    12/8/25 9:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Investment Officer Honigblum Gregg R. bought $34,896 worth of shares (8,200 units at $4.26), increasing direct ownership by 4% to 201,067 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    12/9/25 8:00:05 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Investment Officer Honigblum Gregg R. bought $255,350 worth of shares (65,000 units at $3.93) and was granted 53,867 shares, increasing direct ownership by 161% to 192,867 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    12/8/25 8:00:03 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Investment Officer Honigblum Gregg R. bought $31,900 worth of shares (10,000 units at $3.19), increasing direct ownership by 16% to 74,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    11/10/25 8:00:06 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Trask Kevin

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/10/26 8:45:54 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chairman, President and CEO Olson Eric K.

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/10/26 8:44:43 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Investment Officer Honigblum Gregg R.

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/10/26 8:43:48 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    SEC Filings

    View All

    SiNtx Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Sintx Technologies, Inc. (0001269026) (Filer)

    2/18/26 8:35:38 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by SiNtx Technologies Inc.

    EFFECT - Sintx Technologies, Inc. (0001269026) (Filer)

    12/12/25 12:15:20 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form S-3/A filed by SiNtx Technologies Inc.

    S-3/A - Sintx Technologies, Inc. (0001269026) (Filer)

    12/9/25 5:01:07 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Financials

    Live finance-specific insights

    View All

    SINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational Efficiencies

    Company underscores its strengthened liquidity, cost reductions, and first revenue recorded from OsseoSculpt™  SALT LAKE CITY, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon-nitride–based medical technologies, today provided a business update reporting third quarter financial results in conjunction with the filing the Company's Form 10-Q for the quarter ended September 30, 2025. During the third quarter and subsequent weeks, SINTX advanced a focused commercialization plan centered on infection-resistant silicon nitride devices and polymer composites, while tighteni

    11/13/25 8:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market

    Strategic Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities SALT LAKE CITY, Utah, June 24, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company focused on medical device innovation, today announced that it has executed a Definitive Agreement to acquire the surgical business assets of SiNAPTIC Holdings, LLC, a privately held company focused on silicon nitride ceramic manufacturing and innovation. This transaction is a significant milestone in SINTX's strategy to acquire a potential competitor and drive commercial revenue growth and expand its product portfolio in t

    6/24/25 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Acquires Technology Assessment and Transfer, Inc.

    The Acquisition Broadens Opportunities for SINTX in Aerospace, Defense, and Biomedical Markets SALT LAKE CITY, July 06, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of advanced ceramics, announced the acquisition of Technology Assessment and Transfer, Inc. (TA&T; https://www.techassess.com/), significantly increasing SINTX's capabilities in the aerospace, defense, and biomedical markets. "We are excited to acquire TA&T and take another step towards diversifying and strengthening SINTX," said Dr. Sonny Bal, President and CEO of SINTX. "TA&T will expand our use of advanced manufacturing techno

    7/6/22 9:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer

    Seasoned Healthcare Executive to Lead Strategic Growth Initiatives Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO). In this role, Mr. Honigblum will oversee driving corporate strategy to support SINTX's growth initiatives and enhancing investor relations. Mr. Honigblum brings over 35 years of experience as an executive for emerging growth companies, specializing in the healthcare secto

    11/19/24 6:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by SiNtx Technologies Inc.

    SC 13G - Sintx Technologies, Inc. (0001269026) (Subject)

    4/1/24 4:17:43 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by SiNtx Technologies Inc. (Amendment)

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    2/13/24 8:12:54 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care